158 related articles for article (PubMed ID: 20095432)
1. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
2. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
3. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
4. Engineering of an Iranian
Nikbin VS; Keramati M; Noofeli M; Tayebzadeh F; Kahali B; Shahcheraghi F
J Med Microbiol; 2020 Jan; 69(1):111-119. PubMed ID: 31778110
[No Abstract] [Full Text] [Related]
5. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
6. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
8. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
[TBL] [Abstract][Full Text] [Related]
9. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
[TBL] [Abstract][Full Text] [Related]
10. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
11. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
13. Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein.
Lee SF; Halperin SA; Salloum DF; MacMillan A; Morris A
Infect Immun; 2003 Apr; 71(4):2272-5. PubMed ID: 12654855
[TBL] [Abstract][Full Text] [Related]
14. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.
Nascimento IP; Dias WO; Quintilio W; Christ AP; Moraes JF; Vancetto MD; Ribeiro-Dos-Santos G; Raw I; Leite LC
Microbes Infect; 2008 Feb; 10(2):198-202. PubMed ID: 18248757
[TBL] [Abstract][Full Text] [Related]
15. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
16. Early Protection against Pertussis Induced by Live Attenuated
Debrie AS; Mielcarek N; Lecher S; Roux X; Sirard JC; Locht C
J Immunol; 2019 Dec; 203(12):3293-3300. PubMed ID: 31732529
[TBL] [Abstract][Full Text] [Related]
17. Investigating pertussis toxin and its impact on vaccination.
Coutte L; Locht C
Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice].
Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
Med Dosw Mikrobiol; 2007; 59(2):123-35. PubMed ID: 17929410
[TBL] [Abstract][Full Text] [Related]
19. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
[TBL] [Abstract][Full Text] [Related]
20. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
Mielcarek N; Debrie AS; Mahieux S; Locht C
Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
